Gracell Biotechnologies Inc. (GRCL): Price and Financial Metrics Recent IPO


Gracell Biotechnologies Inc. (GRCL): $13.88

-0.97 (-6.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GRCL to Watchlist
Sign Up

Industry: Beverages


Ranked

of 37

in industry

GRCL Stock Price Chart Interactive Chart >

Price chart for GRCL

GRCL Price/Volume Stats

Current price $13.88 52-week high $33.70
Prev. close $14.85 52-week low $9.75
Day low $13.76 Volume 69,078
Day high $14.88 Avg. volume 138,645
50-day MA $13.38 Dividend yield N/A
200-day MA $0.00 Market Cap 932.92M

Gracell Biotechnologies Inc. (GRCL) Company Bio


Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.


GRCL Latest News Stream


Event/Time News Detail
Loading, please wait...

GRCL Latest Social Stream


Loading social stream, please wait...

View Full GRCL Social Stream

Latest GRCL News From Around the Web

Below are the latest news stories about Gracell Biotechnologies Inc that investors may wish to consider to help them evaluate GRCL as an investment opportunity.

Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of Multiple Myeloma

Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will host a key opinion leader (KOL) webinar on the challenges of treating High Risk Multiple Myeloma and a potential novel approach on Friday, June 11, 2021 at 8:00am Eastern Time.

Yahoo | May 26, 2021

Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June

SUZHOU, China and PALO ALTO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences: Jefferies Virtual Healthcare ConferenceOne-on-one and small group meetings: June 1-4, 2021Fireside chat: June 4, 2021, 8:00 – 8:25 am ETWebcast link: https://ir.gracellbio.com/news-events/events-and-presentationsThe replay of the fireside chat can be accessed through the “News and Events” section of the Gracell Investor website.For more information, please contact your Jefferies representative. Citi Pan-Asia Re...

Yahoo | May 25, 2021

Gracell Biotechnologies Reports First Quarter 2021 Unaudited Financial Results and Provides Corporate Update

Reported updated long-term follow-up data for TruUCAR-enabled CD7-targeted CAR-T product candidate GC027 for the treatment of T-ALL at AACR 2021 Annual Meeting Signed agreement with Lonza to manufacture FasTCAR-enabled product candidates in the U.S. Completed initial public offering of ADSs for net proceeds of US$220 million; US$331.1 million in cash as of March 31, 2021 SUZHOU, China and PALO ALTO, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported its unaudited financial results for the first quarter and recent business highlights. “We are thrilled to have us...

Yahoo | May 17, 2021

Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2020

SUZHOU and SHANGHAI, China, April 23, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2020 with the U.S. Securities and Exchange Commission (“SEC”) on April 23, 2021. The annual report is available on the company’s investor relations website at ir.gracellbio.com and on the SEC’s website at www.sec.gov. The company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor Relations, Gracell Biot...

Yahoo | April 23, 2021

Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting

Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today presented updated long-term follow-up data on their TruUCAR-enabled allogeneic product candidate GC027 for the treatment of adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) in an e-poster presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting on April 10.

Yahoo | April 10, 2021

Read More 'GRCL' Stories Here

GRCL Price Returns

1-mo 14.33%
3-mo -41.78%
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.845 seconds.